Arbutus Biopharma (ABUS) Accounts Payables (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Accounts Payables for 17 consecutive years, with $4.5 million the latest figure, recorded in Q1 2026.

• Quarterly Accounts Payables fell 63.05% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 63.05% YoY) and the FY2025 annual result came in at $5.5 million, down 27.83% from the prior year.
• Accounts Payables declined to $4.5 million in Q1 2026 per ABUS's latest filing, from $5.5 million in the prior quarter.
• Over the last five years, Accounts Payables for ABUS reached as high as $16.0 million in Q4 2022 and fell as low as $4.5 million in Q1 2026.
• A 5-year average of $9.0 million and a median of $8.8 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 49.35% — and 2026, when it slumped 63.05%.
• Year by year, Accounts Payables stood at $16.0 million in 2022, then plunged by 35.92% to $10.3 million in 2023, then retreated by 26.36% to $7.6 million in 2024, then retreated by 27.83% to $5.5 million in 2025, then declined by 18.04% to $4.5 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.5 million, $5.5 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.